Please assess the completion status of the following clinical trial:

Trial Title: Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnoses of breast cancer, with metastases.~* Metastatic lesions should not be curable with surgery or radiotherapy.~* Women of age \> 18.~* To have received a previous treatment with anthracyclines and taxanes.~* A maximum of 2 previous chemotherapy treatment lines for metastatic disease.~* Previous radiotherapy is allowed, whenever the radiated area is not the only disease location.~* At least 4 weeks since the last previous antineoplastic treatment; patient must have recovered from all previous toxicities.~* Performance status \< 2 in World Health Organization (WHO) scale.~* Clinically measurable, non measurable or really non measurable disease, as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria.~* Life expectancy of at least 12 weeks.~* Patients able to comply and to receive an adequate follow-up.~* Adequate bone marrow function: neutrophils ≥ 2 x 10\^9/L; platelets ≥ 100 x 10\^9/L; hemoglobin ≥ 100 g/L.~* Calcium within normal limits.~* Premenopausal women must adopt an adequate contraceptive method during the study and up to 3 months after treatment finalization.~Exclusion Criteria:~* Active infection or serious concomitant disease (investigator's criteria).~* Clinical evidence of metastases in the central nervous system (CNS).~* Blastic bone lesions as only disease.~* Previous neurological toxicity grade 3-4 National Cancer Institute (NCI) Common Toxicity Criteria (CTC) v.2.0.~* Previous treatment with gemcitabine and/or vinorelbine.~* More than 2 previous chemotherapy treatment lines for metastatic disease.~* Abnormal liver function (bilirubin \> 2.0-fold upper normal limit (UNL); alanine transaminase (ALT) and aspartate transaminase (AST) \>2.5-fold UNL). In patients with hepatic metastasis, a value of ALT and AST of up to 5-fold UNL is permitted.~* Unpaired renal function (creatinine \> 2.0 mg/dL).~* Pregnancy or lactating.~* Treatment with any investigational agent in the previous 4 weeks.~* Second malignancy (except for cervix carcinoma in situ or skin carcinoma - no melanoma- with an adequate treatment). Previous malignancies are allowed if disease-free survival is superior to 5 years, except for renal carcinoma or melanoma.~* Males.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Vinorelbine (Type: ACTIVE_COMPARATOR): Arm A: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8.
- Arm B: Vinorelbine and Gemcitabine (Type: EXPERIMENTAL): Arm B: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8. Gemcitabine will be administered following vinorelbine at a dose of 1200 mg/m2 as an intravenous infusion over 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).